Its rare that a company the size of ACG would attract the...

Its rare that a company the size of ACG would attract the attention of not 1 but 2 insto's. Given the market cap's that other listed diagnostic companies command (IPD, NAN etc) we are due for a bit of a rerating here esp when you consider where ACG are at development wise - the risk:reward is too heavily stacked in the investors favour.

Management must be delighted with the insto's on board. I am excited and I don't think the buying will end here. Quality shareholders are a major tick in my investment consideration box!